



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/005,306	11/07/2001	Robert A. Lazarus	P1042C1	6780

9157 7590 12/02/2003

GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CA 94080

EXAMINER

RAO, MANJUNATH N

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 12/02/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<p align="center">Office Action Summary</p>	<p>Application No.</p> <p>10/005,306</p>	<p>Applicant(s)</p> <p>LAZARUS ET AL.</p>	
	<p>Examiner</p> <p>Manjunath N. Rao, Ph.D.</p>	<p>Art Unit</p> <p>1652</p>	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 September 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 21-27 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 21-27 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 07 November 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 21-27 are currently pending and are present for examination.

Election/Restrictions

Applicant's election without traverse of the species in which human DNase I variant comprises the amino acid substitution N74K and SEQ ID NO:9 in Paper filed on 9-18-03 is acknowledged.

Drawings

Drawings submitted in this application are accepted by the Examiner for examination purposes only.

Claim Objections

Claims 21-27 objected to because of the following informalities: Claims continue to be directed non-elected species. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 21-22 and claims 24-27 which depend therefrom are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 21-22 are drawn to DNase variant comprising an amino acid change at position N74 substituted with the

Art Unit: 1652

amino acid K(lys). However, applicants do not provide a SEQ ID NO for the human DNase I without which it would be impossible for the Examiner to do a search rendering it indefinite. Applicants are urged to provide a specific amino acid for the human DNase I in order for the Examiner to do a search.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 21-22 and claims 24-27 which depend therefrom are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

These claims are directed to a genus of variant human polypeptides having DNase I activity comprising a substitution of amino acid N74 with K(lys) and those that have either 90% or 95% sequence identity with such variants. The specification does not contain any disclosure of the structure of all polypeptide sequences included in the claimed genera. The genus of polypeptides claimed is a large variable genus with the potentiality of having many different structures. Therefore, many structurally distinct polypeptides are encompassed within the scope of these claims. The specification discloses only a single species of the claimed genus (i.e., that of SEQ ID NO:1) which is insufficient to put one of skill in the art in possession of the attributes and features of all species within the claimed genus. A sufficient written description of a genus of polypeptides may be achieved by a recitation of a representative number of DNAs defined by

polypeptide sequence or a recitation of structural features common to members of the genus, **which features constitute a substantial portion of the genus.** The recited structural feature of the genus (i.e., a single amino acid change at position 74) does not constitute a substantial portion of the genus as the remainder of the structure of any polypeptide having said activity is completely undefined and the specification does not define the remaining structural features necessary for members of the genus to be selected. Therefore, one skilled in the art cannot reasonably conclude that the applicant had possession of the claimed invention at the time the instant application was filed.

Applicant is referred to the revised guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at www.uspto.gov.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claims 21-23 are rejected under 35 U.S.C. 102(e) as being anticipated by Lazarus et al. (US 6,348,343 B2, issued 2-19-02, effective filing date 2-24-1995). This rejection is based upon

the public availability of a printed publication. Claims 21-23 of the instant application are drawn to a variant human DNase I comprising a substitution of amino acid N74 with lysine(K) (i.e., SEQ ID NO:9). Lazarus et al. teach one such human DNase I variant in which the amino acid Asparagine at position 74 is substituted with amino acid lysine(K) such that the variant enzyme becomes more actin-resistant. Even though the publication does not explicitly disclose amino acid sequence as identical to SEQ ID NO:9, Examiner takes the position that such a characteristic is inherent to the polypeptide and therefore, the polypeptide disclose in the reference has all the amino acid sequence features as claimed in the instant claims. Thus Lazarus et al. anticipate claims 21-27 as written.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 24-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lazarus et al. as applied to claims 21-23 above, and further in view of the common knowledge regarding making homologous amino acid sequences that are wither 90% or 95% identical to a given amino acid sequence. Claims 24-27 are drawn to DNase I variants comprising a single amino acid substitution at position 74 (i.e., N74K) and that are either 90% or 95% identical in amino acid sequence information with said variants.

Lazarus et al. teach the amino acid sequence of a human DNase I. The reference also teaches that substitution of asparagine position 74 with lysine (i.e., N74K) provides an enzyme that is more resistant to actin binding (see column 13). Using such a teaching from the above reference and combining it with the method teachings available in the art, it would have been obvious to those skilled in the art to make homologous amino acid sequences that are either 90% or 95% identical to the amino acid sequence provided by Lazarus et al. One of ordinary skill in the art would have been motivated to do so in order to test said variants for higher resistance to actin binding and its importance for therapeutic applications. One of ordinary skill in the art would have a reasonable expectation of success since Lazarus et al. teach provide the amino acid sequence and said specific mutation and the art provides a number of methods for making homologous sequences that have been used by a number of inventors.

Therefore Lazarus et al. render claims 24-27 *prima facie* obvious to those skilled in the art.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).


Conclusion

None of the claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manjunath N. Rao, Ph.D. whose telephone number is 703-306-5681. The examiner can normally be reached on 7.30 a.m. to 4.00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-306-0196.



Manjunath N. Rao
December 1, 2003